The endovanilloid/endocannabinoid system: A new potential target for osteoporosis therapy

Bone

Volumn 48, Issue 5, 2011, Pages 997-1007

  Rossi, Francesca ^a   Bellini, Giulia ^a   Luongo, Livio ^a   Torella, Marco ^a   Mancusi, Silvia ^a   De Petrocellis, Luciano ^b   Petrosino, Stefania ^b   Siniscalco, Dario ^a   Orlando, Pierangelo ^b   Scafuro, Mariantonietta ^a   Colacurci, Nicola ^b   Perrotta, Silverio ^a   Nobili, Bruno ^a   Di Marzo, Vincenzo ^a   Maione, Sabatino ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

Author keywords

Bone turnover markers; Human bone; Menopause; Osteoclasts; Vanilloid and cannabinoid receptors

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 5' IODORESINIFERATOXIN; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACYLGLYCEROL LIPASE; ANANDAMIDE; ARACHIDONYL 2 CHLOROETHYLAMIDE; BETA ACTIN; CALCIUM ION; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CAPSAICIN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPROTEIN LIPASE; N ACYL PHOSPHATIDYLETHANOLAMINE PHOSPHOLIPASE; PHOSPHOLIPASE; RESINIFERATOXIN; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR AGONIST;

ADULT; ARTICLE; CALCIUM TRANSPORT; CELL ACTIVATION; CELL MEMBRANE; CHANNEL GATING; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MENOPAUSE; MOLECULAR INTERACTION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RECEPTOR DOWN REGULATION; UPREGULATION;

ACID PHOSPHATASE; AMIDOHYDROLASES; BONE AND BONES; CALCIUM; CELL COUNT; CELLS, CULTURED; ENDOCANNABINOIDS; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SPACE; ISOENZYMES; LIGANDS; LIPASE; NF-KAPPA B; OSTEOCLASTS; OSTEOPOROSIS; PHOSPHOLIPASE D; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; TRPV CATION CHANNELS;

EID: 79954624849     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.01.001     Document Type: Article

References (37)

1. Datta H.K., Ng W.F., Walker J.A., Tuck S.P., Varanasi S.S. The cell biology of bone metabolism. J Clin Pathol 2008, 61:577-587.
2. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:504-1508.
3. Zethraeus N., Borgström F., Ström O., Kanis J.A., Jönsson B. Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model. Osteopor Int 2007, 18:9-23.
4. Guggenbuhl P. Osteoporosis in males and females: is there really a difference?. Joint Bone Spine 2009, 76:595-601.
5. Curtis J.R., McClure L.A., Delzell E., Howard V.J., Orwoll E., Saag K.G., Safford M., Howard G. Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med 2009, 24:956-962.
6. Stevenson J.C., Whitehead M.I. Postmenopausal osteoporosis. Br Med J 1982, 285:585-588.
7. Christiansen C., Christensen M.S., Transbøl I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981, 1:459-461.
8. Wasnich R.D., Bagger Y.Z., Hosking D.J., McClung M.R., Wu M., Mantz A.M., Yates J.J., Ross P.D., Alexandersen P., Ravn P., Christiansen C., Santora A.C. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004, 11:622-630.
9. Poole K.E.S., Compston J.E. Osteoporosis and its management. B M J 2006, 333:1251-1256.
10. Pines A. Lifestyle and diet in postmenopausal women. Climacteric 2009, 12:62-65.
11. Compston J. Clinical and therapeutic aspects of osteoporosis. Eur J Radiol 2009, 71:388-391.
12. Rossi F., Siniscalco D., Luongo L., De Petrocellis L., Bellini G., Petrosino S., Torella M., Santoro C., Nobili B., Perrotta S., Di Marzo V., Maione S. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone 2009, 44:476-484.
13. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 2000, 129:227-230.
14. Ahluwalia J., Urban L., Be Test S. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci 2003, 7:2611-2618.
15. Abed E., Labelle D., Martineau C., Loghin A., Moreau R. Expression of transient receptor potential (TRP) channels in human and murine osteoblast-like cells. Mol Membr Biol 2009, 26:146-158.
16. Idris A.I., van't Hof R.J., Greig I.R., Ridge S.A., Baker D., Ross R.A., Ralston S.H. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005, 11:774-779.
17. Idris A.I., Sophocleous A., Landao-Bassonga E., van't Hof R.J., Ralston S.H. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology 2008, 149:5619-5626.
18. Idris A.I., Sophocleous A., Landao-Bassonga E., Canals M., Milligan G., Baker D., van't Hof R.J., Ralston S.H. Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab 2009, 10:139-147.
19. Idris A.I., Landao-Bassonga E., Ralston S.H. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo. Bone 2010, 46:1089-1099.
20. Ryberg E., Vu H.K., Larsson N., Groblewski T., Hjorth S., Elebring T., Sjögren S., Greasley P.J. Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Lett 2005, 579:259-264.
21. Engeli S., Böhnke J., Feldpausch M., Gorzelniak K., Janke J., Bátkai S., Pacher P., Harvey-White J., Luft F.C., Sharma A.M., Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005, 54:2838-2843.
22. Ofek O., Karsak M., Leclerc N., Fogel M., Frenkel B., Wright K., Tam J., Attar-Namdar M., Kram V., Shohami E., Mechoulam R., Zimmer A., Bab I. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 2006, 103:696-701.
23. Bab I., Ofek O., Tam J., Rehnelt J., Zimmer A. Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol 2008, 1:69-74.
24. Bab I., Zimmer A., Melamed E. Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Ann Med 2009, 41:560-567.
25. Karsak M., Cohen-Solal M., Freudenberg J., Ostertag A., Morieux C., Kornak U., Essig J., Erxlebe E., Bab I., Kubisch C., de Vernejoul M.C., Zimmer A. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 2005, 14:3389-3396.
26. Maccarrone M., Rossi S., Bari M., De Chiara V., Fezza F., Musella A., Gasperi V., Prosperetti C., Bernardi G., Finazzi-Agrò A., Cravatt B.F., Centone D. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 2008, 11:152-159.
27. Brown A.J. Novel cannabinoid receptors. Br J Pharmacol 2007, 152:567-575.
28. Whyte L.S., Ryberg E., Sims N.A., Ridge S.A., Mackie K., Greasley P.J., et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci USA 2009, 106:16511-16516.
29. Mackie K., Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 2006, 8:E298-306.
30. Maione S., De Petrocellis L., de Novellis V., Moriello A.S., Petrosino S., Palazzo E., Rossi F.S., Woodward D.F., Di Marzo V. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br. J. Pharmacol. 2007, 150:766-781.
31. Petrosino S., Palazzo E., de Novellis V., Bisogno T., Rossi F., Maione S., Di Marzo V. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacol. 2007, 52:415-422.
32. Premkumar LS, Targeting TRPV1 as an Alternative Approach to Narcotic Analgesics to Treat Chronic Pain Conditions, AAPS J. (2010) Epub ahead of print.
33. Tominaga M., Tominaga T. Structure and function of TRPV1. Pflugers. Arch. 2005, 451:143-150.
34. Garcìa-Sanz N., Fernández-Carvajal A., Morenilla-Palao C., Planells-Cases R., Fajardo-Sánchez E., Fernández-Ballester G., Ferrer-Montiel A. Identification of a tetramerization domain in the C terminus of the vanilloid receptor. J. Neuroscience. 2004, 24:5307-5314.
35. Hermann H., De Petrocellis L., Bisogno T., Schiano Moriello A., Lutz B., Di Marzo V. Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell Mol Life Sci. 2003, 60:607-616.
36. De Petrocellis L., Di Marzo V. Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. Life Sci. 2005, 77:1651-1666.
37. Palazzo E., Staraowicz K., Maione S., Di Marzo V. TRPV1 in neuropathic pain and neurological and neuropsyhiatric disorders. Vanilloid Receptor TRPV1 in drug discovery 2010, John Wiley & Sons, Chapter 10. Faltynek, Gomtsyen (Eds.).